FLT3-ITD mutation failed to transform primary hematopoietic progenitor cells from CDK6-deficient mice, pointing at CDK6 as the prime target of CDK4/6 inhibitors in AML [93]. This evidence concerns the gene CDK6 and acute myeloid leukemia.